ICAD Introduces MRI Products To Help Improve Detection And Diagnosis Of Breast Cancer

Main Category: MRI / PET / Ultrasound
Also Included In: Breast Cancer;  Medical Devices / Diagnostics;  Cancer / Oncology
Article Date: 15 Oct 2008 - 6:00 PDT

email to a friend   printer friendly   view / write opinions

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, will unveil two new MRI products at the 7th Annual Symposium on Advances in Breast MRI in Las Vegas, from October 16-18: SpectraLook™, innovative kinetics technology integrated into iCAD's image analysis solutions for breast and prostate MRI studies; and CADvue™, image review and analysis software designed to improve the analysis workflow, interventional planning and reporting of breast MR results.

"These two new products are the result of leading edge research and development using kinetics technology." said Ken Ferry, President and CEO of iCAD. "We are very excited to expand into this new market offering the most comprehensive detection solutions for breast care and workflow."

SpectraLook™, iCAD's breast MR analysis solution, provides more diagnostic information by creating colorized images based on signal changes defined by tumor physiology. iCAD's All Time Point (ATP) analysis is based on an advanced pharmacokinetic model that calculates numerical values of key physiological parameters, allowing the user to detect the different biological processes taking place in malignant versus benign tumors. These key physiological markers can aid in the analysis of large MR datasets.

CADvue™ image review and analysis software provides maximum functionality facilitating the analysis of ATP colorized images and quantitative data. CADvue allows the user to create standard and customized reports that enable the user to communicate time-sensitive breast MR study results to referring physicians. The reports provide detailed and comprehensive information that is critical to the identification and analysis of abnormalities. 3D colorized images within the report assist clinicians to effectively communicate options to their patients.

"Our SpectraLook and CADvue products will significantly help streamline the radiologist's workflow and the diagnosis process," said Ferry. "Radiologists can look at images easily and quickly, while reducing operating costs and increasing effectiveness of patient care."

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Currently available in more than 2,200 healthcare centers worldwide, iCAD's solutions aid in the early detection of the most prevalent cancers including breast, colon, prostate and in the future, lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.